Dapoxetine

Phase 3Small molecule

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Dapoxetine is one of 60 small molecule programs targeting Erectile Dysfunction. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Erectile DysfunctionActive, not recruiting

Premature EjaculationActive, not recruiting

Erectile DysfunctionPhase 3

Active, not recruiting

Premature EjaculationPhase 3

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Erectile Dysfunction

#DrugCompanyPhaseTrials

Levitra

Bayer

Phase 3

24 2

Zocor

OOrganon and Co

Phase 3

1 3

LCZ696

Novartis

Phase 3

1 4

Botulinum Toxin a

GSK

Phase 3

1 5

Platelet Rich Plasma

ZZagazig University

Phase 3

3 6

Fluvastatin XL

Novartis

Phase 3

1 7

Stem Cells

KKang Stem Biotech Co., Ltd.

Phase 3

1 8

TPN171H

VVigonvita Life Sciences

Phase 3

4 9

Dapoxetine

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

1 10

UK-369,003

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Premature Ejaculation10 trials

Discontinuation of Dapoxetine Treatment in Patients With Premature Ejaculation

Unknown status·PPusan National University Hospital··NCT03018743·200 enrolled

A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00229073·1,116 enrolled

A Study of Withdrawal Effects With Dapoxetine in the Treatment of Premature Ejaculation

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00210613·199 enrolled

Show 7 more trials

A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00210704·1,067 enrolled

Evaluation of the Clinical Efficacy and Safety of Dapoxetine, Combined Dapoxetine With Folic Acid and Combined Dapoxetine With Vitamin B12 in Treatment of Patients With Premature Ejaculation

Completed·SSohag University·Phase 3·NCT04085354·120 enrolled

On-demand Silodosin 4mg vs Dapoxetine 60mg in Treatment of Primary Premature Ejaculation

Completed·—·Phase 2/3·NCT07081659·95 enrolled

The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01063881·285 enrolled

Observational Study of Pharmacological Treatment for Premature Ejaculation Concurrent With Erectile Dysfunction

Unknown status·YYan-Ping Huang·Phase 3·NCT04361305·150 enrolled

A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation.

Completed·AAlza Corporation, DE, USA·Phase 3·NCT00211107·1,294 enrolled

A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation

Completed·AAlza Corporation, DE, USA·Phase 3·NCT00211094·1,320 enrolled

Interaction2 trials

Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 50mg

Completed·SSK Chemicals Co., Ltd.·Phase 1·NCT02485028·36 enrolled

Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg

Completed·SSK Chemicals Co., Ltd.·Phase 1·NCT02485041·36 enrolled

Efficacy1 trial

Safety, Tolerability, Pharmacokinetics and Efficacy of YHD1044

Completed·YYuhan Corporation·Phase 1/2·NCT01419470·24 enrolled

Erectile Dysfunction1 trial

Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT01063855·495 enrolled

Treatment1 trial

An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation

Completed·AAlza Corporation, DE, USA·Phase 3·NCT01230762·1,774 enrolled

1 more indication

Clinical Trial1 trial

Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine

Unknown status·DDong-A Pharmaceutical Co., Ltd.·Phase 1·NCT01928563·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Dapoxetine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dapoxetine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dapoxetine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson Pharmaceutical Research & Development, L.L.C. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Dapoxetine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Premature Ejaculation10 trials

Interaction2 trials

Efficacy1 trial

Erectile Dysfunction1 trial

Treatment1 trial

Clinical Trial1 trial

References

Drug Info

Quick Facts

Related News